This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Wall Street Bulls Look Optimistic About Novo Nordisk (NVO): Should You Buy?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Novo Nordisk (NVO). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Aprea (APRE) Rises on Advancing Lead Drug to Clinical Studies
by Zacks Equity Research
Aprea Therapeutics (APRE) advances its novel macrocyclic ATR inhibitor into early-stage clinical studies for treating advanced solid tumors.
Amarin's (AMRN) Q4 Preliminary Revenues Top Expectations
by Zacks Equity Research
Amarin Corporation (AMRN) expects to generate total revenues in the range of $88-$90 million in fourth-quarter 2022. Share price rises following the announcement.
AstraZeneca (AZN) Set to Acquire CinCor Pharma for $1.3B
by Zacks Equity Research
AstraZeneca's (AZN) CinCor Pharma buyout is going to add blood pressure drug baxdrostat to its cardiorenal pipeline.
Novo Nordisk (NVO) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Novo Nordisk (NVO) closed at $137.23 in the latest trading session, marking a -1.02% move from the prior day.
Why You Should Hold Elevance Health (ELV) in Your Portfolio
by Zacks Equity Research
Elevance Health (ELV) remains well-poised for growth due to a growing customer base within its Government and IngenioRx businesses coupled with solid cash-generating abilities.
Q4 Earnings Season: Global Week Ahead
by John Blank
Corporate America starts reporting fourth-quarter results and investors will be looking for signs of a potential economic slowdown filtering through to companies' bottom lines.
FDA Accepts Pfizer's (PFE) sBLA Filing for Pneumococcal Jab
by Zacks Equity Research
The FDA grants priority review to Pfizer's (PFE) filing seeking label expansion of its pneumococcal 20-valent conjugate vaccine in infants and children. A decision is expected by this April.
HCA Healthcare (HCA) Rises 43% in 6 Months: More Room to Run?
by Zacks Equity Research
HCA Healthcare (HCA) is well-poised for growth due to growing patient volumes, acquisitions and adequate cash-generating abilities.
Is Novo Nordisk (NVO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Novo Nordisk (NVO) and Acumen Pharmaceuticals, Inc. (ABOS) have performed compared to their sector so far this year.
The Zacks Analyst Blog Highlights Alphabet, Adobe, TotalEnergies, Novo Nordisk and Diageo
by Zacks Equity Research
Alphabet, Adobe, TotalEnergies, Novo Nordisk and Diageo are included in this Analyst Blog.
Top Analyst Reports for Alphabet, Novo Nordisk & TotalEnergies
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Adobe Inc. (ADBE) and TotalEnergies SE (TTE).
Novo Nordisk (NVO) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Novo Nordisk (NVO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Best Momentum Stock to Buy for January 5th
by Zacks Equity Research
NVO, SSEZY and LBRT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 5, 2023.
New Strong Buy Stocks for January 5th
by Zacks Equity Research
AAL, DLNG, BNPQY, NVO and SAP have been added to the Zacks Rank #1 (Strong Buy) List on January 5 , 2023.
Here is Why Growth Investors Should Buy Novo Nordisk (NVO) Now
by Zacks Equity Research
Novo Nordisk (NVO) could produce exceptional returns because of its solid growth attributes.
What Makes Novo Nordisk (NVO) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Novo Nordisk (NVO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here's How Much You'd Have If You Invested $1000 in Novo Nordisk a Decade Ago
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Beat the Market Like Zacks: JPMorgan Chase, Oracle, BioVie in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
The Zacks Analyst Blog Highlights Novo Nordisk, AstraZeneca, Accenture, Chubb and Roper Technologies
by Zacks Equity Research
Novo Nordisk, AstraZeneca, Accenture, Chubb and Roper Technologies are part of the Zacks top Analyst Blog.
Top Research Reports for Novo Nordisk, AstraZeneca & Accenture
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), AstraZeneca PLC (AZN) and Accenture plc (ACN).
Beat the Market Like Zacks: Vivint, Caterpillar, Oracle in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Zacks Investment Ideas feature highlights: Novo Nordisk
by Zacks Equity Research
Novo Nordisk has been highlighted in this Investment Ideas article.
Zacks Industry Outlook Highlights Johnson & Johnson, Novo Nordisk, Merck and AstraZeneca
by Zacks Equity Research
Johnson & Johnson, Novo Nordisk, Merck and AstraZeneca have been highlighted in this Industry Outlook article.
Simplify Your Investing Process Using This Top-Down Approach
by Bryan Hayes
Letting the market guide us rather than trying to predict what will happen is the most prudent course of action.